-+ 0.00%
-+ 0.00%
-+ 0.00%

PFIZER’S ELREXFIO OUTPERFORMS STANDARD REGIMENS AND MEETS PRIMARY ENDPOINT IN PHASE 3 STUDY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Reuters·10/27/2026 10:46:06